Quest Diagnostics Inc
DUS:QDI
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
22B USD |
Loading...
|
|
| US |
|
CVS Health Corp
NYSE:CVS
|
96.8B USD |
Loading...
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
67.3B EUR |
Loading...
|
|
| US |
|
Cigna Corp
NYSE:CI
|
70.4B USD |
Loading...
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
26.5B EUR |
Loading...
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23.1B EUR |
Loading...
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21.7B USD |
Loading...
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11B EUR |
Loading...
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.2B USD |
Loading...
|
|
| US |
|
DaVita Inc
NYSE:DVA
|
10.3B USD |
Loading...
|
|
| AU |
|
Sonic Healthcare Ltd
ASX:SHL
|
10.5B AUD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Quest Diagnostics Inc
Glance View
In the rapidly evolving world of healthcare, Quest Diagnostics Inc. stands as a pivotal player, shaping the future of diagnostic services. Born out of a quest for innovation in clinical testing, Quest Diagnostics operates at the intersection of medical science and cutting-edge technology. The company has a wide-reaching network of laboratories and service centers, offering a comprehensive array of diagnostic testing solutions that range from routine blood tests to advanced genetic screening. Their services are not limited to hospitals and physician offices; they extend into a variety of sectors including pharmaceuticals, food, and global business services, completing over a hundred million clinical laboratory tests annually. Quest's robust infrastructure and commitment to precision ensure that patients and healthcare providers receive timely and accurate information that is crucial for early detection, diagnosis, and informed treatment decisions. Quest Diagnostics' revenue model is straightforward yet effective, driven primarily by service fees from its expansive menu of tests. By collaborating with insurers, healthcare providers, and employers, Quest ensures broad access to its services. Moreover, the company continually invests in research and development to expand its test portfolio and enhance the quality of its services, thus staying competitive in the fast-paced healthcare environment. Through strategic acquisitions and partnerships, Quest has broadened its geographical reach and bolstered its technological capabilities, maintaining its position as an industry leader. As healthcare increasingly leans toward personalized medicine and preventive care, Quest Diagnostics is poised to leverage its analytical prowess and deep repository of health data to drive future growth and innovation, serving as an indispensable ally in global public health.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Quest Diagnostics Inc is 33.2%, which is below its 3-year median of 33.3%.
Over the last 3 years, Quest Diagnostics Inc’s Gross Margin has decreased from 35.1% to 33.2%. During this period, it reached a low of 32.9% on Sep 30, 2024 and a high of 35.1% on Dec 31, 2022.